| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30085618 | HIV | ENSG00000007171.19 | protein_coding | NOS2 | No | No | 4843 | P35228 |
| TVIS44042313 | HTLV-1 | ENSG00000007171.19 | protein_coding | NOS2 | No | No | 4843 | P35228 |
| TVIS44042312 | HTLV-1 | ENSG00000007171.19 | protein_coding | NOS2 | No | No | 4843 | P35228 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NOS2 |
|---|---|
| DrugBank ID | DB00155 |
| Drug Name | Citrulline |
| Target ID | BE0000005 |
| UniProt ID | P35228 |
| Regulation Type | |
| PubMed IDs | 10906995; 10944418; 11742852; 10906994; 12745988 |
| Citations | Cunningham JM, Rayne RC: Radiochemical measurement of NOS activity by conversion of [14C]L-arginine to citrulline using HPLC separation. Methods Mol Biol. 1998;100:75-81.@@Keilhoff G, Reiser M, Stanarius A, Aoki E, Wolf G: Citrulline immunohistochemistry for demonstration of NOS activity in vivo and in vitro. Nitric Oxide. 2000 Aug;4(4):343-53.@@Conrad KP, Powers RW, Davis AK, Novak J: Citrulline is not the major product using the standard "NOS activity" assay on renal cortical homogenates. Am J Physiol Regul Integr Comp Physiol. 2002 Jan;282(1):R303-10.@@Knowles RG, Salter M: Measurement of NOS activity by conversion of radiolabeled arginine to citrulline using ion-exchange separation. Methods Mol Biol. 1998;100:67-73.@@Yi GB, McClendon D, Desaiah D, Goddard J, Lister A, Moffitt J, Meer RK, deShazo R, Lee KS, Rockhold RW: Fire ant venom alkaloid, isosolenopsin A, a potent and selective inhibitor of neuronal nitric oxide synthase. Int J Toxicol. 2003 Mar-Apr;22(2):81-6. |
| Groups | Investigational; Nutraceutical |
| Direct Classification | L-alpha-amino acids |
| SMILES | N[C@@H](CCCNC(N)=O)C(O)=O |
| Pathways | Citrullinemia Type I; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Argininemia; Hyperornithinemia with Gyrate Atrophy (HOGA); Canavan Disease; Hypoacetylaspartia; Hyperprolinemia Type II; Argininosuccinic Aciduria; L-Arginine:Glycine Amidinotransferase Deficiency; Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Prolidase Deficiency (PD); Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Carbamoyl Phosphate Synthetase Deficiency; Ornithine Aminotransferase Deficiency (OAT Deficiency); Hyperprolinemia Type I; Aspartate Metabolism; Nitric Oxide Signaling Pathway; Arginine and Proline Metabolism; Ornithine Transcarbamylase Deficiency (OTC Deficiency); Prolinemia Type II; Urea Cycle |
| PharmGKB | PA164747225 |
| ChEMBL | CHEMBL444814 |
